A systematic review of recent phase-II trials in refractory or recurrent osteosarcoma: can we inform future trial design?
High-grade osteosarcoma is an aggressive bone sarcoma with a peak incidence in adolescence [1], with one-third of the patients experiencing disease progression/recurrence during or after first-line treatment consisting of multidrug chemotherapy and surgery of the primary tumor and metastatic lesions [2 –5]. At progression or recurrence, the 5-year overall survival (OS) is dismal, below 30%, with an extremely poor prognosis, unless a second complete surgical remission is achieved [2,3]. Despite many trials being performed, there is no established standard therapy besides surgery for recurrent/ref ractory osteosarcoma, nor is it known in which clinical scenarios systemic therapy might be of benefit [6–9].
Source: Cancer Treatment Reviews - Category: Cancer & Oncology Authors: Roelof van Ewijk, Morgane Cleirec, Nikolas Herold, Marie-C écile le Deley, Natasha van Eijkelenburg, Pascaline Boudou-Rouquette, Severine Risbourg, Sandra J. Strauss, Emanuela Palmerini, Kjetil Boye, Leo Kager, Stefanie Hecker-Nolting, Antonin Marchais, Tags: Systematic or Meta-analysis Studies Source Type: research
More News: Bone Cancers | Cancer | Cancer & Oncology | Chemotherapy | Osteosarcoma | Sarcomas | Study